Taneja S, Duseja A, Mehta M, et al. - In chronic hepatitis C (CHC) patients with end stage renal disease (ESRD) on maintenance hemodialysis (MHD), researchers conducted this real‐life prospective study to test the safety and effectiveness of sofosbuvir plus velpatasvir fixed dose combination. Participants in the study were 51 CHC patients with ESRD on MHD. All patients were treated with full-dose sofosbuvir (400 mg) plus velpatasvir (100 mg) fixed dosed combination administered daily for 12 weeks, regardless of genotype, involvement of cirrhosis, or treatment status (naive or experienced). According to findings, the median HCV RNA level in 51 CHC patients (males 41 [80.4%], mean age 42.8 ± 14.6 years) was 2.0 x10⁶ IU/ml. In patients with ESRD on MHD, sofosbuvir + velpatasvir fixed-dose combination is safe and effective in the treatment of CHC. Ultimately 49 patients (96%) achieved SVR 12. All 51 patients tolerated the sofosbuvir +velpatasvir combination, with none of the patients reporting any serious adverse event.